Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
6,303.00
-22.00 (-0.35%)
Oct 22, 2025, 3:45 PM IDT
-0.35%
Market Cap71.66B
Revenue (ttm)56.02B
Net Income (ttm)-528.98M
Shares Outn/a
EPS (ttm)-0.47
PE Ration/a
Forward PE7.37
Dividendn/a
Ex-Dividend Daten/a
Volume767,277
Average Volume1,368,080
Open6,300.00
Previous Close6,325.00
Day's Range6,257.00 - 6,310.00
52-Week Range4,865.00 - 8,431.00
Beta0.71
RSI46.21
Earnings DateNov 5, 2025

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

Formycon, Teva Pharma Launch FYB201/Ranivisio Biosimilar In Pre-filled Syringe In Europe

(RTTNews) - Formycon AG (FYB.F), Bioeq AG and Teva Pharmaceutical Industries Ltd. (TEVA) on Tuesday announced the launch of FYB201/Ranivisio or ranibizumab in Europe as the first Lucentis biosimilar a...

1 day ago - Nasdaq

Teva (TEVA) Partners with Prestige Biopharma for Tuznue in Europe

Teva (TEVA) Partners with Prestige Biopharma for Tuznue in Europe

1 day ago - GuruFocus

Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige's Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) market...

1 day ago - GlobeNewsWire

Teva Vs. Viatris: Who Will Dominate In President Trump's America?

Teva Pharmaceuticals and Viatris occupy leading positions in the generic drugs market, valued at more than $613 billion in 2030. Each of them has advantages and "dark spots" in their portfolios of FDA...

4 days ago - Seeking Alpha

AFI Development

Teva Pharmaceutical Industries Astellas Pharma 3000 . AFI Flex . , . , Teva 305 ( 1840 .) , Astellas 150 ( 1000 .) . AFI Development, , . Teva, Astellas.

6 days ago - Vedomosti (Ведомости)

TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder

Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.

9 days ago - Nasdaq

Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults

(RTTNews) - Teva Pharmaceuticals, the U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), in collaboration with Medincell (MEDCL.PA), announced that the U.S. Food and Drug Administration has...

11 days ago - Nasdaq

FDA Expands Use of Teva's (TEVA) Uzedy for Bipolar I Disorder

FDA Expands Use of Teva's (TEVA) Uzedy for Bipolar I Disorder

11 days ago - GuruFocus

FDA Approves Teva's (TEVA) Uzedy for Bipolar I Disorder Maintenance

FDA Approves Teva's (TEVA) Uzedy for Bipolar I Disorder Maintenance

11 days ago - GuruFocus

FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder

PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell (E...

11 days ago - GlobeNewsWire

IDEV, SPOT, TEVA, AER: Large Inflows Detected at ETF

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI International Developed Markets ETF (Symbol: IDEV) w...

11 days ago - Nasdaq

Harel Insurance Investments & Financial Services Ltd. ...

Harel Insurance Investments & Financial Services Ltd. Increases Stake in Teva Pharmaceutical Industries Ltd.

12 days ago - GuruFocus

Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs

The Trump administration is reportedly planning to exclude imported generic drugs from tariffs. White House spokesman Kush Desai told the Wall Street Journal that "the administration is not actively d...

13 days ago - Benzinga

Teva Pharmaceutical: Turnaround Driven By Huge Pipeline Upside

Teva Pharmaceutical Industries is regaining investor interest as restructuring efforts drive margin improvements. Read why TEVA stock is a Buy.

15 days ago - Seeking Alpha

FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors

FDA Initiative May Impact Teva's (TEVA) Generic Drug Endeavors

18 days ago - GuruFocus

JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News

JP Morgan Maintains Overweight Rating on TEVA, Price Target Raised to $26 | TEVA Stock News

19 days ago - GuruFocus

Unpacking the Latest Options Trading Trends in Teva Pharmaceutical Indus

Investors with a lot of money to spend have taken a bullish stance on Teva Pharmaceutical Indus (NYSE: TEVA). And retail traders should know. We noticed this today when the trades showed up on public...

21 days ago - Benzinga

Notable ETF Inflow Detected - IXUS, PDD, NU, TEVA

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core MSCI Total International Stock ETF (Symbol: IXUS) where w...

21 days ago - Nasdaq

Teva Releases Q3 2025 Aide Memoire

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its...

26 days ago - GlobeNewsWire

Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial re...

26 days ago - GlobeNewsWire

Teva Pharmaceuticals: Pipeline Momentum Signals New Era For Investors

Wall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment ma...

26 days ago - Seeking Alpha

November 7th Options Now Available For Teva Pharmaceutical Industries (TEVA)

Investors in Teva Pharmaceutical Industries Ltd (Symbol: TEVA) saw new options begin trading today, for the November 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and ...

26 days ago - Nasdaq

TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News

TEVA's Price Target Raised to $26 by UBS, Rating Maintained at 'Buy' | TEVA Stock News

27 days ago - GuruFocus

Is Teva Pharmaceutical Indus Gaining or Losing Market Support?

Teva Pharmaceutical Indus's (NYSE: TEVA) short interest as a percent of float has risen 9.14% since its last report. According to exchange reported data, there are now 50.51 million shares sold short...

4 weeks ago - Benzinga